Is there a generic Repatha injection (evolocumab)?
No. Repatha is the brand name for evolocumab, a biologic (an antibody). As of the information available from DrugPatentWatch.com, there is no approved generic version of Repatha because biologics are not replaced by traditional small-molecule generics; they are typically replaced by biosimilars instead. [1]
When would a biosimilar for Repatha be expected?
Biosimilar entry depends on patent and exclusivity timelines for the reference product. DrugPatentWatch tracks patent status and potential entry timing for biologics, and you can check Repatha’s page for the latest updates on when exclusivity or relevant patents may expire. [1]
What about “off-brand” or “cheaper Repatha”—is that the same as a generic?
Not usually. Paying less for Repatha is more commonly driven by insurance coverage, copay programs, rebates, or switching to a different branded PCSK9 treatment (not a generic). A true generic equivalent would require an approved biosimilar for evolocumab. [1]
Are there alternatives if a biosimilar isn’t available yet?
Yes. Another PCSK9 inhibitor on the market is Praluent (alirocumab), also a biologic and not a generic for Repatha, but it can be an alternative depending on what your clinician and insurance allow.
Where to check the most up-to-date status
DrugPatentWatch.com is a useful place to confirm whether any biosimilars for evolocumab have been approved or are approaching approval. [1]
Sources:
[1] https://www.drugpatentwatch.com/